重组人促红细胞生成素治疗肾性贫血的疗效观察

Clinical Outcomes of Recombinant Human Erythropoietin in Treatment of Renal Anemia

目的观察国产rhEPO环尔博治疗肾性贫血的疗效,分析影响其疗效的部分因素。方法未行透析的肾性贫血患者46例采用环尔博5000U皮下注射2次/周治疗。治疗前及治疗期间每4周观察血常规、血清电解质、肾功能、血压的变化及不良反应,治疗前和治疗结束后观察甲状旁腺素(PTH)、C反应蛋白(CRP)。结果与治疗前相比患者的血红蛋白从第4周开始增加(P<0.05或0.01),并随着治疗的进行逐渐升高,而肾功能、电解质、血压等与治疗前相比差异无统计学意义(P>0.05)。46例患者全部完成治疗,无脱落,其中显效28例,有效10例,无效8例。结论 rhEPO治疗肾性贫血的疗效确定,炎症反应、甲状旁腺功能亢进对其疗效产生影响。

Objective To evaluate the clinical efficacy of recombinant human erythropoietin （rhEPO） in treatment of patients with renal anemia due to chronic kidney failure, and to investigate influence factors of renal anemia. Methods 46 patients with chronic kidney failure associated with renal anemia were involved in this study. The patients were given subcutaneous rhEPO （5 000 U,twice per week） for 12 weeks. The efficacy of all patients was recorded every two weeks during treatment of twelve weeks. Results Compared with pretreatment：the elevated levels of hemoglobin and hematocrit （Hot） were found from week 2, there were statistically significant differences （P 〈 0.05 or 0.01 ）. While the levels of kidney function, serum potassium and blood pressure compared to pretreatment, were no statistically significant differences（ P 〉 0.05 ）. The excellent curative was found in 28 cases, the good curative was 10 eases, and the ineffective was 8 cases. Conclusion rhEPo in treatment of renal anemia was safe and effective.